Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

A composite biomarker for esophageal cancer risk from automated analysis of a non-endoscopic device

View ORCID ProfileAdam G. Berman, View ORCID ProfileRebecca C. Fitzgerald, View ORCID ProfileFlorian Markowetz
doi: https://doi.org/10.1101/2021.08.20.21262366
Adam G. Berman
1Cancer Research UK Cambridge Institute, University of Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Adam G. Berman
Rebecca C. Fitzgerald
2Medical Research Council Cancer Unit, University of Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rebecca C. Fitzgerald
Florian Markowetz
1Cancer Research UK Cambridge Institute, University of Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Florian Markowetz
  • For correspondence: florian.markowetz@cruk.cam.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Barrett’s esophagus containing intestinal metaplasia predisposes to cancer, yet the majority of cases are undiagnosed. The length of a Barrett’s segment is a key indicator of cancer risk, but measuring it has so far relied on endoscopy, which is expensive and invasive. Cytosponge-TFF3 is a minimally-invasive test that identifies intestinal metaplasia for endoscopic confirmation. We report a machine learning technique to quantify the extent of intestinal metaplasia and predict Barrett’s segment length from whole-slide image tile counts automatically generated from Cytosponge-TFF3 histology slides. Utilizing data from 529 patients, our segment length prediction model achieves an average validation fold accuracy of 0.84. Applying this algorithm to an independent test set of 162 patients from a screening trial shows a precision of 0.90 for identifying short-segment disease. This advance will enable higher-risk patients to be prioritized for endoscopy while saving more than half of Cytosponge-TFF3-positive patients from endoscopy in the screening setting.

Competing Interest Statement

R.C.F is named on patents related to Cytosponge-TFF3 that have been licensed by the Medical Research Council to Covidien (now Medtronic). RCF is a founder and shareholder of Cyted Ltd. FM is a founder, director and shareholder of Tailor Bio.

Clinical Trial

ISRCTN12730505, ISRCTN68382401

Clinical Protocols

https://github.com/markowetzlab/barretts-segment-length-predictor

Funding Statement

This research was supported by Cancer Research UK (FM: C14303/A17197), a Medical Research Council programme grant (RCF: RG84369) and Cambridge University Hospitals NHS Foundation Trust. BEST2 was funded by Cancer Research UK (12088 and 16893). We would also like to thank the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014) and the Experimental Cancer Medicine Centre for their support. AGB acknowledges support from a Gates Cambridge Scholarship from the Bill & Melinda Gates Foundation. FM is a Royal Society Wolfson Research Merit Award holder.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

BEST2: Ethics approval was obtained from the East of England - Cambridge Central Research Ethics Committee (number 10/H0308/71) and registered in the UK Clinical Research Network Study Portfolio (9461). BEST3: Ethics approval was obtained from the East of England - Cambridge Central Research Ethics Committee (number 16/EE/0546).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵a These authors share senior authorship

Data Availability

The data and fully documented code to perform all of the analyses of this paper can be found at this public repository in the form of two illustrative Jupyter notebooks: https://github.com/markowetzlab/barretts-segment-length-predictor

https://github.com/markowetzlab/barretts-segment-length-predictor

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted August 25, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
A composite biomarker for esophageal cancer risk from automated analysis of a non-endoscopic device
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
A composite biomarker for esophageal cancer risk from automated analysis of a non-endoscopic device
Adam G. Berman, Rebecca C. Fitzgerald, Florian Markowetz
medRxiv 2021.08.20.21262366; doi: https://doi.org/10.1101/2021.08.20.21262366
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
A composite biomarker for esophageal cancer risk from automated analysis of a non-endoscopic device
Adam G. Berman, Rebecca C. Fitzgerald, Florian Markowetz
medRxiv 2021.08.20.21262366; doi: https://doi.org/10.1101/2021.08.20.21262366

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Gastroenterology
Subject Areas
All Articles
  • Addiction Medicine (228)
  • Allergy and Immunology (506)
  • Anesthesia (110)
  • Cardiovascular Medicine (1244)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (532)
  • Epidemiology (10027)
  • Forensic Medicine (5)
  • Gastroenterology (500)
  • Genetic and Genomic Medicine (2462)
  • Geriatric Medicine (238)
  • Health Economics (479)
  • Health Informatics (1645)
  • Health Policy (753)
  • Health Systems and Quality Improvement (636)
  • Hematology (250)
  • HIV/AIDS (535)
  • Infectious Diseases (except HIV/AIDS) (11871)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (253)
  • Medical Ethics (75)
  • Nephrology (268)
  • Neurology (2289)
  • Nursing (139)
  • Nutrition (352)
  • Obstetrics and Gynecology (454)
  • Occupational and Environmental Health (537)
  • Oncology (1248)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (325)
  • Pediatrics (733)
  • Pharmacology and Therapeutics (314)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2281)
  • Public and Global Health (4840)
  • Radiology and Imaging (838)
  • Rehabilitation Medicine and Physical Therapy (492)
  • Respiratory Medicine (651)
  • Rheumatology (286)
  • Sexual and Reproductive Health (240)
  • Sports Medicine (227)
  • Surgery (268)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)